arbutus biopharma - ARBU

ARBU

Close Chg Chg %
0.00 0.00 0.00%

Closed Market

0.00

0.00 (0.00%)

Volume: 700.00

Last Updated:

Apr 29, 2026, 9:31 AM EDT

Company Overview: arbutus biopharma - ARBU

ARBU Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.00

Market Cap

$0.00

Shares Outstanding

699.00K

Public Float

582.10K

Beta

32.03

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$4.00

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

N/A

 

ARBU Performance

No Data Available

ARBU Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About arbutus biopharma - ARBU

American Business Corp. operates as a development stage company, which has no specific business plan or purpose and has indicated that its business plan is to engage in a merger or an acquisition with an unidentified company. The company was founded on January 16, 1987 and is headquartered in Louisville, KY.

ARBU At a Glance

American Business Corp.
11921 Brinley Avenue
Louisville, Kentucky 40243
Phone 1-502-410-6900 Revenue 0.00
Industry Miscellaneous Net Income -2,929,664.00
Sector Miscellaneous Employees N/A
Fiscal Year-end 12 / 2007
View SEC Filings

ARBU Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -69.541
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.965

ARBU Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

ARBU Liquidity

Current Ratio 0.00
Quick Ratio 0.00
Cash Ratio 0.00

ARBU Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -23,739.276
Return on Equity N/A
Return on Total Capital 24.418
Return on Invested Capital N/A

ARBU Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -190.164
Total Debt to Total Assets 281,881.789
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Arbutus Biopharma - ARBU

Collapse All in section
All values USD millions. 2003 2004 2005 2006 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
5.37K 2.28K 4.55K 9.11K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
5.37K 2.28K 4.55K 9.11K
Depreciation
5.37K 2.28K 4.55K 9.11K
Amortization of Intangibles
- - - -
-
COGS Growth
+303.84% -57.57% +100.00% +100.00%
Gross Income
(5.37K) (2.28K) (4.55K) (9.11K)
Gross Income Growth
-303.84% +57.57% -100.00% -100.00%
Gross Profit Margin
- - - -
-
2003 2004 2005 2006 5-year trend
SG&A Expense
553.37K 862.47K 396.03K 340.06K
Research & Development
- - - -
-
Other SG&A
553.37K 862.47K 396.03K 340.06K
SGA Growth
+3,201.53% +55.86% -54.08% -14.13%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(558.74K) (864.74K) (400.58K) (349.17K)
Non Operating Income/Expense
- - - -
-
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
111.26K 112.65K 2.57M 2.58M
Interest Expense Growth
-81.83% +1.25% +2,183.96% +0.29%
Gross Interest Expense
111.26K 112.65K 2.57M 2.58M
Interest Capitalized
- - - -
-
Pretax Income
(670.00K) (977.40K) (2.97M) (2.93M)
Pretax Income Growth
-6.28% -45.88% -204.23% +1.48%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(670.00K) (977.40K) (2.97M) (2.93M)
Minority Interest Expense
- - - -
-
Net Income
(670.00K) (977.40K) (2.97M) (2.93M)
Net Income Growth
-6.28% -45.88% -204.23% +1.48%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - 2.70M
-
Discontinued Operations
- - - 2.70M
-
Net Income After Extraordinaries
(670.00K) (977.40K) (271.55K) (2.93M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(670.00K) (977.40K) (271.55K) (2.93M)
EPS (Basic)
-1 -1 -0.001 -4
EPS (Basic) Growth
- - +99.90% -399,900.00%
-
Basic Shares Outstanding
543.71K 650.24K 698.71K 698.71K
EPS (Diluted)
-0.001 -1 -0.001 -4
EPS (Diluted) Growth
+99.90% -99,900.00% +99.90% -399,900.00%
Diluted Shares Outstanding
1.55M 650.24K 698.71K 698.71K
EBITDA
(553.37K) (862.46K) (396.03K) (340.06K)
EBITDA Growth
-3,201.73% -55.86% +54.08% +14.13%
EBITDA Margin
- - - -
-

Arbutus Biopharma in the News